216 related articles for article (PubMed ID: 7386280)
1. Partial agonism of prostaglandin H2 analogs and 11-deoxy-prostaglandin F2 alpha to thromboxane-sensitive preparations.
Jones RL; Wilson NH
Adv Prostaglandin Thromboxane Res; 1980; 6():467-75. PubMed ID: 7386280
[No Abstract] [Full Text] [Related]
2. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
Hornberger WB; Patscheke H
Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
Harris RH; Nichols R; Schmeling JW; Ramwell PW
Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
[No Abstract] [Full Text] [Related]
6. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
[TBL] [Abstract][Full Text] [Related]
7. A 16-p-fluorophenoxy prostanoid with potent and long-lasting thromboxane-like actions [proceedings].
Jones RL; Wilson NH
Br J Pharmacol; 1978 Jun; 63(2):362P. PubMed ID: 667444
[No Abstract] [Full Text] [Related]
8. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
Patscheke H; Stegmeier K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
[No Abstract] [Full Text] [Related]
9. Vasoconstrictor response of arterioles of the hamster cheek pouch to norepinephrine, prostaglandin H2, F2 alpha and carbocyclic thromboxane A2, a possible thromboxane A2 analogue.
Herrmann KS
Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):180-5. PubMed ID: 6960809
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting prostaglandin endoperoxide transformation: antibodies against PGH2.
Fitzpatrick FA; Pike JE
Prog Lipid Res; 1981; 20():179-82. PubMed ID: 7342082
[No Abstract] [Full Text] [Related]
11. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
12. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium.
Pollock WK; Armstrong RA; Brydon LJ; Jones RL; MacIntyre DE
Biochem J; 1984 May; 219(3):833-42. PubMed ID: 6234886
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin H2 directly lowers human platelet cAMP levels.
Rybicki JP; Le Breton GC
Thromb Res; 1983 Jun; 30(5):407-14. PubMed ID: 6310815
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations.
Coleman RA; Humphrey PP; Kennedy I; Levy GP; Lumley P
Br J Pharmacol; 1981 Jul; 73(3):773-8. PubMed ID: 7248665
[TBL] [Abstract][Full Text] [Related]
16. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982.
Samuelsson B
Biosci Rep; 1983 Sep; 3(9):791-813. PubMed ID: 6315101
[No Abstract] [Full Text] [Related]
17. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
Mevkh AT; Basevich VV; Varfolomeev SD
Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
[TBL] [Abstract][Full Text] [Related]
18. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues.
Morinelli TA; Niewiarowski S; Kornecki E; Figures WR; Wachtfogel Y; Colman RW
Blood; 1983 Jan; 61(1):41-9. PubMed ID: 6293626
[No Abstract] [Full Text] [Related]
19. [The antithromboxane activity of alpha- and omega-modified carbocyclic analogs of PGH1].
Kuz'mitskiĭ BB; Bondar' NF; Malaeva LP
Eksp Klin Farmakol; 1992; 55(4):31-3. PubMed ID: 1458183
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure of the platelet aggregation factor thromboxane A2.
Bhagwat SS; Hamann PR; Still WC; Bunting S; Fitzpatrick FA
Nature; 1985 Jun 6-12; 315(6019):511-3. PubMed ID: 4000279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
